Iovance (IOVA) COO Igor Bilinsky Exercises RSUs; Shares Withheld

What Happened
Igor Bilinsky, Chief Operating Officer of Iovance Biotherapeutics (IOVA), had 8,789 restricted stock units (RSUs vest) converted into common stock on September 1, 2026. Of those, 4,472 shares were withheld by the company to satisfy mandatory tax withholding at an effective per-share value of $8.28 (total withheld value $37,028). The vesting/conversion is reported as a derivative exercise/conversion (code M) with the withholding recorded as a disposition for tax purposes (code F). This was not an open-market sale.

Key Details

• Transaction date: 2026-09-01; filing date: 2026-09-03.
• RSUs converted: 8,789 shares (each RSU = 1 share).
• Shares withheld for taxes: 4,472 shares at $8.28/share = $37,028 (company withholding, not an open-market sale).
• Shares remaining from this vested grant after withholding: 4,317 shares (8,789 − 4,472).
• Footnotes: F1–F6 indicate these were vested RSUs, withholding was mandatory and not a market sale, remaining RSUs will vest quarterly, and the numbers reflect the March 1, 2024 RSU grant.
• No indication in the filing of a late report; transaction-to-filing gap was two days.

Context
This was a routine RSU vesting event converted to shares with cashless tax withholding by the issuer. For retail investors, note this is not a purchase signal — it’s a standard compensation-related conversion and the withholding is to cover tax liability, not a market sale by the insider.